what is the success rate of immunotherapy for breast cancer

Release time ：Dec-17,2024

The efficacy of immunotherapy in treating breast cancer is typically influenced by multiple factors, including the cancer's subtype, stage, the patient's overall health, and the presence of any comorbidities. Generally, immunotherapy may be beneficial for certain breast cancer patients, but its benefits are not universal.

In particular, immunotherapy has demonstrated promise in treating triple-negative breast cancer (TNBC). For instance, the use of PD-1/PD-L1 inhibitors in conjunction with chemotherapy may enhance progression-free survival and overall survival rates in patients. However, there is considerable variability in the effectiveness of immunotherapy even among this patient group. Moreover, for breast cancers that are hormone receptor-positive or HER2-positive, immunotherapy may not be as effective as alternative treatments, such as endocrine therapy or targeted therapy.

Consequently, physicians consider a comprehensive assessment of a patient's condition and health status when contemplating immunotherapy for breast cancer to determine the most suitable treatment plan. Patients undergoing immunotherapy should closely monitor their responses and side effects and adjust their treatment protocols under medical supervision. Additionally, maintaining healthy lifestyle practices, such as a balanced diet and regular exercise, can contribute to improved therapeutic outcomes and overall quality of life.